Mobile

Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-N...

Update Il y a 4 ans
Reference: EUCTR2013-002780-26

Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

- To evaluate the steady state pharmacokinetics (PK) for elvitegravir and tenofovir alafenamide and confirm the dose of the E/C/F/TAF single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV) treatment-naive adolescents. - To evaluate the safety and tolerability of the E/C/F/TAF STR through Week 24 in HIV-1 infected, ARV treatment-naive adolescents

Inclusion criteria

  • Human Immunodeficiency Virus (HIV-1) Infection